METABOLIC & WEIGHT RESEARCH / COLOPHON
About This Research Desk
A side-by-side, citation-anchored weighing of the AOD-9604, tesamorelin, and tirzepatide record. Nothing sold here, no exam room, no dose to copy.
What Smart Choice Peptides is
Smart Choice Peptides sets three metabolic peptides side by side and reads each against its own trial record: AOD-9604, tesamorelin, and tirzepatide, with tirzepatide leading the desk. These three do not share a mechanism — one is a growth-hormone fragment, one amplifies the body's own growth-hormone signal, and one is a dual gut-hormone receptor agonist — but they share a category in how they are marketed and discussed, and that makes a side-by-side, evidence-first treatment useful.
The organizing purpose here is calibration, not persuasion: to tell a reader, in plain language and with citations, what each compound was actually tested on, in whom, and how the result came out — including the one that came out negative. AOD-9604's human obesity trials did not beat placebo. Tesamorelin's approval is narrow and specific. Tirzepatide's is broad and, so far, unmatched in magnitude within this trio. Each compound has its own page; a comparison page lines up the three directly; and one shared references list aggregates every source used across the whole site.
How this desk is compiled
Three editorial principles govern what appears here. First, every research claim is tied to a numbered citation drawn from peer-reviewed journals, clinical-trial publications, regulatory monographs, or established clinical-reference sources, collected on the references page with DOIs and PubMed links where available. Second, evidence is described at its actual strength and in its actual population — a finding from a rabbit osteoarthritis model is labeled as such, a small mechanism trial is not written as though it were an outcomes trial, and a negative trial result is reported as plainly as a positive one. Third, community-reported experiences are always kept textually separate from the cited clinical evidence, labeled anecdotal, and never used to imply a dose or a recommendation.
What it is not
This desk keeps no storefront, no exam room, no telehealth line, and no order counter. It brokers no compound, holds no affiliate or referral tie to any manufacturer, telehealth provider, or research-chemical supplier, and hands no reader a diagnosis, a prescription, or a dose. Tesamorelin and tirzepatide are prescription medicines available only through licensed medical providers, for their specific approved indications. AOD-9604 is not approved anywhere and its human efficacy for weight loss was not established in trials; any product described as 'research-grade AOD-9604' falls outside any approved quality or safety standard. For clinical guidance, the right stop is a licensed healthcare provider. Editorial corrections and citation questions can be directed to the contact page.